Flagship Biosciences, a fast growing pharmaceutical services company based in Flagstaff, AZ, is a leading example of the power of the collaborative nature of the Arizona bioindustry.Continue reading
Many trademark applicants are getting official looking notices from scam artists. These notices make it appear that the notice is from the United States Patent and Trademark Office. Unless carefully examined these notices can fool just about anyone.Continue reading
Disruptive innovations and unsustainable costs propel life sciences companies into the behavioral change business
The full potential of personalized medicine requires both medical and behavioral scienceContinue reading
ASU CONECTR, an established network of high quality clinical research sites in Arizona, assists organizations in the placement and conduct of clinical trials. Committed to excellence in clinical research processes, CONECTR sites have a track record of rapid study start-up, faster contract and regulatory turnaround times, and successful patient enrollment. For more information about CONECTR, go to www.conectr.org .Continue reading
This year, technology and business organizations, including AZBio worked together with Congress to reauthorize the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program. Sean Greene, Associate Administrator for Investment and Special Advisor for Innovation at the U.S. Small Business Administration, has recently shared his thoughts on what comes next on the SBA Community Blog…Continue reading
Arizona’s Bioscience Sector is Blooming. View online or download the updated presentation that leaders of Arizona’s bioscience industry are using statewide. Continue reading
The development of a new drug is a long, complicated process involving up to 15 years of research and, in many cases, hundreds of millions of dollars. There are two distinct processes that every drug must go through before reaching the general patient population and treating a specific disease – Drug Discovery and Drug Development.Continue reading
The City of Maricopa’s 5th Annual Economic Development Summit sheds light on new developments and the future economy.
On Thursday December 8, 2011, the City of Maricopa held its 5th Annual Economic Development Summit. Over 100 attendees were present, representating the development, land investment, business, and real estate sectors as well as local stakeholder group.Continue reading
Estimated at $20B, the Medial Device Tax was included in the Affordable Care Act that was signed into law by President Obama in 2010. The amount is based on a 2.3% excise tax that will be levied on the total revenues of a company, regardless of whether a company generates a profit, starting in 2013.
While many industry groups including AZBio, AdvaMed, and MDMA have been sharing information on why this tax is unwise and have worked to explain the negative effects that it could have on innovation and patient care, there is always the possibility that it will not be repealed before 2013.
Ernst and Young recently published a Tax Note on the Medical Device Tax that gives a comprehensive overview of what it is, who it affects and how they will be affected. The tax note is provided below as published by E&Y and is shared with permission.Continue reading